$21.1M capital deployed

32% primary ownership

Jun '11 initial capital deployed

return to top

Why NovaSom?

Headquartered in Glen Burnie, MD, NovaSom is a leader in Obstructive Sleep Apnea (“OSA”) home testing with the AccuSom® home sleep test, the only comprehensively supported home sleep test that provides continuous patient support and next-day test results and interpretation for health care professionals.

The FDA-cleared AccuSom is as accurate as sleep-lab testing and significantly more convenient and comfortable for patients. Patients are able to test around their own schedules and can sleep in their own beds, which helps eliminate “first-night” effect and improves data collection. Safeguard has deployed $21.1 million in NovaSom since June 2011 and has a 32% primary ownership position.

The OSA diagnostic market in the U.S. is estimated to be approximately $4 billion and is growing more than 15% annually. Only 3 million sufferers in the U.S. have been diagnosed to date, out of an estimated 40 million moderate to severe OSA sufferers.

During the third quarter of 2015, chief medical officer Michael Coppola, M.D. was elected as a fellow of the American College of Physicians for his extensive achievement in sleep and pulmonary medicine, public health policy, patient advocacy and scholarly activities over the past 25 years. NovaSom’s AccuSom home sleep test is being featured in an episode of Innovations with Ed Begley Jr. on the Discovery Channel. AccuSom is currently covered for more than 150 million commercially insured U.S. lives. NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center & Telehealth Provider and is classified by the Centers for Medicare & Medicaid Services as an Independent Diagnostic Testing Facility.

(Updated as of 09/30/15)

By giving patients the option to conduct tests for OSA in their homes, we hope to identify and treat more of the millions of undiagnosed sufferers. Safeguard’s financial and operational support have augmented our traction to date, expanded our market penetration and ultimately impacted our patients’ quality of life.

– John Spitznagel, CEO, NovaSom